Myelodysplastic syndromes (MDS) are probably the most common hematologic malignancies in adults over the age of 60 and are a major source of morbidity and mortality among older age groups. Diagnosis and management of this chronic blood cancer has evolved significantly in recent years and there are Food and Drug Administration-approved therapies that can extend patients' life expectancy and improve quality of life. Primary care physicians (PCPs) are often involved in the process of diagnosis and follow-up of MDS patients, especially those in low-risk groups. They can therefore play an important role in improving patient care and quality of life by ensuring early referral and participating in supportive management. There is also a shortage of oncologists which increases the importance of the role of PCPs in management of MDS patients. In the face of limited resources, PCPs can improve access and quality of care in MDS patients. This article provides an overview of the common manifestations, diagnostic approaches, and therapeutic modalities of MDS for PCPs, with a focus on when to suspect MDS, when a referral is appropriate, and how to provide appropriate supportive care for patients diagnosed with MDS.
malignancy in adults 60 years of age and older in the United
States, affecting about 1 in 500 people in this age group. 1) About
15,000 new cases of MDS are diagnosed annually in the United
States, and with the number of people over the age of 65 expected to double by 2030, this number is expected to increase.
2) It is important for primary care physicians (PCPs) to recognize the signs and symptoms of MDS because they are often patients' first point of contact in the health care system. PCPs therefore play an important role in ensuring early referral and diagnosis of MDS patients. There is also a shortage of oncologists which increases the importance of the role of PCPs in care of MDS patients. 3) It has been shown that more than 90% of PCPs co-manage comorbid conditions, evaluate and treat depression, establish do not resuscitate, refer to hospice, and prescribe opiates in cancer patient management, though they are generally less involved in treatment decision making. 4) In this article, we will review the common manifestations, diagnostic work-up, and management
INTRODUCTION
Myelodysplastic syndromes (MDS) are a heterogeneous group of acquired clonal stem cell disorders that cause ineffective and dysplastic production of blood cells and can transform to acute myeloid leukemia (AML). MDS is most common in older age groups and is probably the most common hematological 2)
The cities of Hiroshima and Nagasaki, Japan report higher than average rates of MDS, especially among those exposed to radiation from the atomic bombs when they were young.
5)
Cigarette smoking, which is the greatest non occupational source of benzene exposure, has also been associated with greater MDS risk in several studies. 6) Secondary, or therapy-related, MDS (t-MDS) accounts for about 10% of all MDS cases and has a worse prognosis than de novo MDS.
2) It typically occurs after chemotherapy or radiation treatment for a previous cancer, or following prolonged use of immunosuppressive drugs in patients with autoimmune disorders or organ transplantation. Among MDS patients with one or more primary tumors, the most common types of primary tumor include non-Hodgkin or Hodgkin lymphoma, acute lymphoblastic lymphoma, and cancers of the breast, prostate, urinary system, and lung or bronchus. 7, 8) The median time from diagnosis of the primary tumor to the diagnosis of MDS is 4.5 years.
7)
Two of the most common and best understood forms of t-MDS occur after treatment with alkylating agents and topoisomerase II inhibitors. T-MDS following treatment with alkylating agents typically presents as MDS with monosomy 7, del(5q), or monosomy 5, after a latency period of about 5 to 7 years. T-MDS is also occasionally found after treatment with topoisomerase II inhibitors, but more commonly the patient presents with full-blown AML after a latency period of just 1 to 3 years. Topoisomerase II inhibitors are associated with translocations involving chromosome bands 11q23 or 21q22. 12) while a smaller study in Korea found a median age of 57. 13) Both studies also reported different clinical profiles than those of a typical Western patient, and suggested a combination of genetic and environmental factors that likely account for the differences.
In the absence of other known risk factors, PCPs should have the highest index of suspicion for MDS in older, Caucasian men.
CLINICAL PRESENTATION
Patients with MDS can be asymptomatic, and their disease may be diagnosed only after incidental finding of cytopenias in a routine blood test. The most common cytopenia associated with MDS is anemia, which is found in about 80% to 85% of patients. 14) Anemia associated with MDS is usually macrocytic (Figure 1 ) or normocytic. 14) Most symptomatic patients display classic symptoms and signs of anemia, such as pallor, 
APPROACH TO DIAGNOSIS OF MDS IN PRIMARY CARE SETT INGS
MDS can be difficult to diagnose due to the high rate of co Cytogenetic abnormalities are detected in about 45% to 50% of MDS patients 14) and the specific abnormality found can have important implications for prognosis and treatment. bone marrow blasts. 19) To assist in the diagnostic process, a set of minimum diagnostic criteria has been established for MDS. In order to establish a diagnosis of MDS, two 'prerequisite' criteria must be fulfilled, as well as at least one out of three possible decisive criteria.
20)
The AML: acute myeloid leukemia.
*Median time to 25% AML evolution. 21) In most cases, the treatment goals for patients with MDS will be to prevent or delay the transformation to AML and to improve the patient's quality of life. The only proven curative therapeutic modality is allogeneic hematopoietic stem cell transplant (allo-SCT). About 35% to 40% of patients who undergo this treatment experience a long-term remission. 16) Unfortunately, the rate of transplant-related mortality remains high and many patients are not eligible for the treatment due to advanced age and/or the presence of co-morbidities. 14) As a result, allo-SCT is typically performed in less than 5% of patients. 
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